<?xml version="1.0" encoding="UTF-8"?>
<p>Roscovitine, (2
 <italic>R</italic>)-2-{[6-(benzylamino)-9-isopropyl-9
 <italic>H</italic>-purin-2-yl]amino}-1-butanol also called CY-202 or seliciclib, is a low molecular weight purine derivative with a characteristic ring structure. It belongs to cyclin-dependent kinase (CDK) protein inhibitors, which play a key role in regulating the cell cycle, promoting its progression or transition between the individual phases
 <xref rid="CIT0032" ref-type="bibr">
  <sup>32</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0033" ref-type="bibr">
  <sup>33</sup>
 </xref>. Roscovitine has been shown to possess anticancer activity in various 
 <italic>in vitro</italic> and 
 <italic>in vivo</italic> models
 <xref rid="CIT0034" ref-type="bibr">
  <sup>34</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0035" ref-type="bibr">
  <sup>35</sup>
 </xref>. The antitumor action of this chemotherapeutic has been tested using cancer xenografts of LoVo human CRC cells, MESSA-DX5 human uterine carcinoma cells, or MDA-MB 231 human breast cancer cells grafted into CD1 nude mice
 <xref rid="CIT0036" ref-type="bibr">
  <sup>36</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0037" ref-type="bibr">
  <sup>37</sup>
 </xref>.
</p>
